ATRA Atara Biotherapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ATRA

Price (delayed)

$13.31

Market cap

$1.11B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.15

Enterprise value

$925.36M

Sector: Healthcare
Industry: Biotechnology
Website: http://www.atarabio.com/

Highlights

The equity has surged by 59% year-on-year and by 31% since the previous quarter
The EPS has increased by 27% YoY and by 10% from the previous quarter
Atara Biotherapeutics's quick ratio has decreased by 33% QoQ and by 14% YoY
The net income has decreased by 5% YoY

Key stats

What are the main financial stats of ATRA
Market
Shares outstanding
83.61M
Market cap
$1.11B
Enterprise value
$925.36M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.24
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$306.61M
EBITDA
-$296.82M
Free cash flow
-$185.27M
Per share
EPS
-$4.15
Free cash flow per share
-$2.5
Book value per share
$5.95
Revenue per share
$0
TBVPS
$7.95
Balance sheet
Total assets
$588.12M
Total liabilities
$125.78M
Debt
$13.04M
Equity
$462.34M
Working capital
$440.37M
Liquidity
Debt to equity
0.03
Current ratio
6.31
Quick ratio
6.06
Net debt/EBITDA
0.63
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-71.3%
Return on equity
-84.6%
Return on invested capital
-103.6%
Return on capital employed
-60.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ATRA stock price

How has the Atara Biotherapeutics stock price performed over time
Intraday
0.23%
1 week
-2.85%
1 month
-11.5%
1 year
53.7%
YTD
-32.2%
QTD
-7.31%

Financial performance

How have Atara Biotherapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$309.05M
Net income
-$306.62M
Gross margin
N/A
Net margin
N/A
The net income has decreased by 5% YoY
The operating income has contracted by 4.5% YoY

Growth

What is Atara Biotherapeutics's growth rate over time

Valuation

What is Atara Biotherapeutics stock price valuation
P/E
N/A
P/B
2.24
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 27% YoY and by 10% from the previous quarter
The equity has surged by 59% year-on-year and by 31% since the previous quarter
The price to book (P/B) is 28% lower than the 5-year quarterly average of 3.1 and 14% lower than the last 4 quarters average of 2.6

Efficiency

How efficient is Atara Biotherapeutics business performance
The company's return on assets rose by 20% YoY and by 13% QoQ
The company's return on equity rose by 18% YoY and by 11% QoQ
Atara Biotherapeutics's return on invested capital has increased by 14% YoY and by 5% QoQ

Dividends

What is ATRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATRA.

Financial health

How did Atara Biotherapeutics financials performed over time
ATRA's total liabilities has surged by 144% since the previous quarter and by 141% year-on-year
The total assets has soared by 71% YoY and by 45% from the previous quarter
The debt is 97% less than the equity
The equity has surged by 59% year-on-year and by 31% since the previous quarter
ATRA's debt to equity is down by 40% year-on-year and by 25% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.